PDS Biotechnology price to book ratio PDSB

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 11.1×; Aug 2026
10-year median: 3.1×
10-year range: 0.2× to 19.2×
Peer median: 1.5×

PDS Biotechnology's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Aug 2026, at 11.1×.

On the days it had one over the last ten years, its median was 3.1×, from 0.2× in Mar 2020 to 19.2× in May 2026.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	11.1×	2.8×	19.2×
2025	4.7×	2.1×	5.0×
2024	2.9×	2.6×	8.4×
2023	6.3×	3.5×	8.0×
2022	8.0×	1.6×	8.0×
2021	3.4×	1.7×	11.7×
2020	1.5×	0.2×	3.0×
2019	1.1×	0.3×	1.7×
2018	0.3×	0.3×	8.5×
2017	3.9×	2.5×	4.4×
2016	3.7×	1.6×	3.7×

Against its peers

Companies in Drug Manufacturers - General nearest PDS Biotechnology's size, closest first, today.

Company	Price to book ratio
PDSBPDS Biotechnology	n/m
SPROSpero Therapeutics	1.5×
LFVNLifevantage	2.2×
ATNMActinium Pharmaceuticals	1.6×
NATRNatures Sunshine Products	1.3×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
Peer median	1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on PDS Biotechnology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.